N-acyl nitrogen heterocyles as ligands of peroxisome proliferator-activated receptors
    1.
    发明申请
    N-acyl nitrogen heterocyles as ligands of peroxisome proliferator-activated receptors 失效
    N-酰基氮杂环素作为过氧化物酶体增殖物激活受体的配体

    公开(公告)号:US20060135593A1

    公开(公告)日:2006-06-22

    申请号:US10556988

    申请日:2004-05-19

    IPC分类号: A61K31/405 A61K31/401

    摘要: Compounds of the formula provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis, Crohn's disease, and conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.

    摘要翻译: 配方的化合物提供与过氧化物酶体增殖物激活受体(PPAR)结合的药理学试剂。 因此,本发明的化合物可用于治疗由哺乳动物中的PPAR受体活性介导的病症。 这些病症包括血脂异常,高脂血症,高胆固醇血症,动脉粥样硬化,高甘油三酯血症,心力衰竭,心肌梗塞,血管疾病,心血管疾病,高血压,肥胖症,炎症,关节炎,癌症,阿尔茨海默病,皮肤病,呼吸系统疾病,眼科疾病,炎症性肠病 ,溃疡性结肠炎,克罗恩病,以及涉及葡萄糖耐量降低,高血糖症和胰岛素抵抗的病症,例如1型和2型糖尿病和X综合症。

    HETEROCYCLIC COMPOUNDS AND METHODS OF USE
    2.
    发明申请
    HETEROCYCLIC COMPOUNDS AND METHODS OF USE 审中-公开
    杂环化合物和使用方法

    公开(公告)号:US20070135502A1

    公开(公告)日:2007-06-14

    申请号:US11619936

    申请日:2007-01-04

    摘要: Compounds of the formula provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X. Preferred are the compounds of the invention which are dual agonists of PPARα and PPARγ receptors.

    摘要翻译: 配方的化合物提供作为过氧化物酶体增殖物激活受体(PPARs)的有效激动剂的药理学试剂。 因此,本发明的化合物可用于治疗由哺乳动物中的PPAR受体活性介导的病症。 这些病症包括血脂异常,高脂血症,高胆固醇血症,动脉粥样硬化,高甘油三酯血症,心力衰竭,心肌梗死,血管疾病,心血管疾病,高血压,肥胖症,炎症,关节炎,癌症,阿尔茨海默病,皮肤病,呼吸系统疾病,眼科疾病,炎症性肠病 ,溃疡性结肠炎和克罗恩病。 本发明的化合物在哺乳动物中特别可用作降血糖药,用于治疗和预防葡萄糖耐量降低,高血糖症和胰岛素抵抗等疾病,如1型和2型糖尿病,以及X综合征。 是本发明的化合物,它们是PPARα和PPARγ受体的双重激动剂。

    Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
    3.
    发明申请
    Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds 失效
    苯磺酰氨基化合物和含有这些化合物的药物组合物

    公开(公告)号:US20070043020A1

    公开(公告)日:2007-02-22

    申请号:US10563708

    申请日:2004-07-07

    CPC分类号: C07D413/12

    摘要: Compounds of the formula provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease, and conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.

    摘要翻译: 配方的化合物提供与过氧化物酶体增殖物激活受体(PPAR)结合的药理学试剂。 因此,本发明的化合物可用于治疗由哺乳动物中的PPAR受体活性介导的病症。 这些病症包括血脂异常,高脂血症,高胆固醇血症,动脉粥样硬化,高甘油三酯血症,心力衰竭,心肌梗塞,血管疾病,心血管疾病,高血压,肥胖症,炎症,关节炎,癌症,阿尔茨海默病,皮肤病,呼吸系统疾病,眼科疾病,炎症性肠病 (IBD),溃疡性结肠炎和克罗恩氏病,以及涉及葡萄糖耐量降低,高血糖症和胰岛素抵抗的病症,如1型和2型糖尿病,以及综合征X.

    Organic compounds
    4.
    发明申请
    Organic compounds 失效
    有机化合物

    公开(公告)号:US20070004704A1

    公开(公告)日:2007-01-04

    申请号:US10570338

    申请日:2004-09-16

    摘要: Compounds of the formula provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the present invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.

    摘要翻译: 配方的化合物提供与过氧化物酶体增殖物激活受体(PPAR)结合的药理学试剂。 因此,本发明的化合物可用于治疗由哺乳动物中的PPAR受体活性介导的病症。 这些病症包括血脂异常,高脂血症,高胆固醇血症,动脉粥样硬化,高甘油三酯血症,心力衰竭,心肌梗塞,血管疾病,心血管疾病,高血压,肥胖症,炎症,关节炎,癌症,阿尔茨海默病,皮肤病,呼吸系统疾病,眼科疾病,炎症性肠病 (IBDs),溃疡性结肠炎和克罗恩病。 本发明的化合物在哺乳动物中特别可用作降血糖药,用于治疗和预防葡萄糖耐量降低,高血糖症和胰岛素抵抗等疾病,如1型和2型糖尿病和X综合征。